Oncology Intelligence Digest June 09, 2026 GSK struck a massive $10.6 billion deal to acquire Nuvalent, securing zidesamtinib…
Oncology Intelligence Membership Required
You must be a Oncology Intelligence member to access this content.
Already a member? Log in here